Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)-Reference-Cited by-同舟云学术

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

Published:2018-02-12 Issue:4 Volume:20 Page:760-768
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Mogensen Ulrik M.¹²,Gong Jianjian³,Jhund Pardeep S.¹,Shen Li¹,Køber Lars²,Desai Akshay S.⁴,Lefkowitz Martin P.³,Packer Milton⁵,Rouleau Jean L.⁶,Solomon Scott D.⁴,Claggett Brian L.⁴,Swedberg Karl⁷,Zile Michael R.⁸,Mueller-Velten Guenther⁹,McMurray John J.V.¹

Affiliation:

1. BHF Cardiovascular Research Centre; University of Glasgow; Glasgow UK

2. Rigshospitalet Copenhagen University Hospital; Copenhagen Denmark

3. Novartis Pharmaceutical Corporation; East Hanover NJ USA

4. Cardiovascular Medicine; Brigham and Women's Hospital; Boston MA USA

5. Baylor Heart and Vascular Institute; Baylor University Medical Center; Dallas TX USA

6. Institut de Cardiologie de Montréal; Université de Montréal; Montréal Canada

7. Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden, and National Heart and Lung Institute; Imperial College; London UK

8. Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center; Charleston SC USA

9. Novartis Pharma AG; Basel Switzerland

Funder

Hjerteforeningen

Novartis

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference21 articles.

1. Key issues in end point selection for heart failure trials: composite end points;Neaton;J Card Fail,2005

2. Time to move on from ‘time-to-first’: should all events be included in the analysis of clinical trials?;Anker;Eur Heart J,2012